| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4737 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 |
| filingDate |
2015-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017515896-A |
| titleOfInvention |
Methods of treatment of inflammatory bowel disease |
| abstract |
Disclosed are methods for treating IBD subjects with anti-SMAD7 therapy, such as SMAD7 antisense oligonucleotides, to reduce CRP levels. Also disclosed is a method of treating and managing IBD in a subject using anti-SMAD7 therapy, such as SMAD7 antisense oligonucleotides, based on CRP levels. Also disclosed is a method of determining whether an IBD subject is responsive or likely to be responsive to treatment with an anti-SMAD7 therapy. A decrease in CRP levels may correlate with a decrease in IBD remission or CDAI score. The invention also relates to the treatment of IBD using anti-SMAD7 therapies (eg, antisense oligonucleotides) in combination with additional agents. The invention also features related pharmaceutical compositions and kits. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018502107-A |
| priorityDate |
2014-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |